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ABSTRACT
Myelofibrosis is a reactive, often inhomogeneous process in the marrow cavity, and sampling errors on biopsies
obtained to diagnose and monitor the course of myelofibrosis have been a constant problem in hematopathol-
ogy. We investigated the potential utility of magnetic resonance imaging (MRI) of the lumbar spine, pelvis, and
femora as a diagnostic and monitoring technique for assessment of myelofibrosis. Findings on serial marrow
biopsies were correlated with T1-weighted spin-echo and short inversion time inversion recovery (STIR)
images in patients with chronic idiopathic myelofibrosis or myelofibrosis developing from polycythemia vera or
essential thrombocythemia who underwent hematopoietic cell transplantation (HCT). Thirty-five patients
were studied before HCT; 11 were followed for 3 months and 10 patients for >1 year after HCT with
sequential marrow biopsies and MRI studies. MRI allowed direct visualization of the biopsy sites and corre-
lation of histologic and MRI findings. MRI also provided assessment of the extent and degree of myelofibrosis
in a large volume of the skeletal marrow. There was good correlation between biopsy results and MRI findings
at specific biopsy sites and between successful HCT and resolution of fibrosis and osteosclerosis as determined
by MRI. We conclude that in patients with myelofibrosis, MRI of the skeleton provides a comprehensive
assessment of the pattern and extent of fibrosis and allows for correlation with biopsy findings. In patients
undergoing HCT, MRI accurately reflects response or progression of marrow disease.
© 2006 American Society for Blood and Marrow Transplantation
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sNTRODUCTION
Fibrosis of the bone marrow is a reactive process that
ay develop in patients with various malignant and non-
alignant disorders [1]. It is an essential feature of
hronic idiopathic myeloﬁbrosis with myeloid metapla-
ia and a frequent ﬁnding in advanced polycythemia vera
nd essential thrombocythemia. Chronic idiopathic
yeloﬁbrosis, polycythemia vera, and essential throm-
ocythemia are chronic myeloid disorders [2] and are
enerally easily controlled over extended periods with
onservative management. However, for more advanced
isease, few treatment options are available, and the only kurrent strategy with curative potential is hematopoietic
ell transplantation (HCT) [3-6].
A major concern in previous studies of HCT was
hat myeloﬁbrosis would interfere with engraftment of
onor cells because of the severely damaged microen-
ironment in the marrow cavity. Some studies have
upported that notion [7]. However, although the
ime course of donor cell engraftment tends to be
lower than in patients without ﬁbrosis, more recent
rials have shown that marrow ﬁbrosis is not a signif-
cant risk factor for graft failure [8-10]. Marrow ﬁbro-
is generally regresses after HCT [5,6], although the
inetics have been poorly characterized.
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G. E. Sale et al.1286Unfortunately, the sampling error with needle bi-
psies of the marrow is high because myeloﬁbrosis is
n inherently heterogeneous process. Even sampling
f 5 marrow sites at autopsy, totaling up to 1700 mm2
ross-sectional areas of medullary marrow, shows
reat variation, although such extensive sampling
ields approximately 100 times the area (volume) of a
ample obtained by standard needle biopsies in a living
atient, which average 15 mm2 at best. In contrast, the
eld of view of a magnetic resonance imaging (MRI)
tudy of the pelvis covers 3-4 vertebral bodies, iliac
ones, femoral heads, and proximal femoral shafts.
ombined, these areas cover 200 cm2 of bone com-
ared with 17 cm2 for a 5-specimen autopsy marrow
xamination or 0.15 cm2 in a needle biopsy. The needle
iopsy, in other words, samples only 1/1200 of the area
isualized by a pelvic MRI. In addition, MRI obtained
fter the marrow biopsy documents the needle track and,
hus, the site of marrow sampling; hence, the combina-
ion of marrow biopsy and MRI allows a precise assess-
ent of the extent and pattern of ﬁbrosis and provides an
ndication of whether or not the marrow biopsy was
epresentative of the overall marrow appearance.
The present study was intended to improve the
ssessment and staging of marrow ﬁbrosis in patients
ndergoing HCT, to describe the kinetics of resolu-
ion of the marrow pathology, and to correlate these
ndings with the clinical course of patients after
CT. We also investigated whether MRI was capable
f assessing the response of marrow ﬁbrosis to alloge-
eic HCT. We report data on the concurrent assess-
ent of myeloﬁbrosis by histology and MRI in 35
atients, 21 of whom were reassessed sequentially for
3 months after allogeneic or autologous HCT.
ETHODS
atients
Thirty-ﬁve patients were enrolled. Patient and
isease characteristics are summarized in Table 1.
hromosome analysis showed a normal karyotype in
6 patients, abnormalities of chromosome 20 in 4,
bnormalities of chromosome 9 in 3, complex abnor-
alities in 3, and various structural or numerical ab-
ormalities in 9. In 1 patient, the karyotype could not
e determined.
tudy Design
All patients underwent bone marrow biopsies
rom the posterior iliac crests before HCT and were
cheduled to undergo sequential biopsies after HCT.
he protocol called for biopsies followed within 2-3
ays by pelvic MRI. The initial biopsy and MRI were
btained within 2-3 weeks before HCT, again at 3
onths, and 1-2 years after transplantation. We wereble to complete this sequence in 10 patients to 1 Wear after transplantation and in an additional 11 pa-
ients to 3 months. Among the remaining 14 patients,
did not undergo transplantation, and 11 declined to
ave repeat marrow biopsies or MRI after HCT or
ere unable to return to the transplantation center for
e-evaluation.
arrow Biopsies
Marrow core biopsies were obtained in standard
ashion from the posterior iliac crests with a Jamshidi
iopsy needle. The patient was prone and received
ocal anesthesia with bicarbonate buffered lidocaine.
able 1. Patient, Disease, and Transplant Characteristics
Characteristic Number of Patients
umber of patients 35
ge (y), range (median) 25-66 (51)
ale/female 16/19
iagnosis
CIMF 19
ET 9
PV 7
isease duration (ms), range (median) 6-313 (25)
ille stage at HCT*
0 17
1 13
2 2
ytogenetics†
Normal 16
Abnormal (see text) 18
onor‡
HLA-identical sibling 12
HLA-identical unrelated 17
Syngeneic twin 1
Autologous 2
onditioning regimen
tBUCY (ATG) 26 (10)
FlutBU (ATG) 2 (1)
BU 2
BU TBI 1
FluBU 1
VHD prophylaxis
CSP/MTX 27
Other 2
None 3
ource of stem cells:
Peripheral blood 28
Bone marrow 4
o transplantation 3
TG, antithymocyte globulin; BU, busulfan; CIMF, chronic idio-
pathic myeloﬁbrosis; CSP, cyclosporine; ET, essential throm-
bocythemia; Flu, ﬂudarabine; FlutBU, ﬂudarabine plus targeted
busulfan; GVHD, graft-versus-host disease; HCT, hematopoi-
etic cell transplantation; MTX, methotrexate; PV, polycythemia
vera; TBI, total body irradiation; tBUCY, targeted busulfan plus
cyclophosphamide.
As described by Dupriez et al [18]; also applied to patients with
prior polycythemia vera or essential thrombocythemia. Data
were incomplete for 3 patients.
Information missing in 1 patient.
Three patients did not receive transplants.ith subsequent biopsies, care was taken to avoid
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MRI for Myelofibrosis 1287revious biopsy sites. After touch preparation, the
iopsy was ﬁxed in B5 or formalin and brieﬂy decal-
iﬁed before parafﬁn embedding. Histologic assess-
ent of myeloﬁbrosis was based on sections stained
ith hematoxylin and eosin in parallel with reticulin
ilver and periodic acid-Schiff stains on all biopsy
ections at 5 m using standard histologic microtomy
ethods. Marrow ﬁbrosis was graded as described
lsewhere [11,12]. Trichrome stains were not rou-
inely performed because this stain is not speciﬁc and
s not used in the scale for myeloﬁbrosis by Dekme-
ian et al [12]. In addition to reticulin and collagen
brosis, extent of osteosclerosis was determined. Be-
ause currently there is no universally accepted clas-
iﬁcation scheme for osteosclerosis, we devised a semi-
uantitative grading for the present study (Table 2).
he minimum requirement for including biopsy sam-
les for measurement was the presence of 4 intact
rabeculae 1 mm deep to the cortex of the bone. A
tage micrometer was used to calibrate an eye micro-
eter. Estimates of the trabecular width were made at
ight angles to the axis of the trabecula being measured
t multiple points along each measurable trabecula.
ore advanced cases showed knobby expanded ends on
he trabeculae in addition to increased width.
Aspirate smears and particle sections were also
repared whenever specimens were adequate. Sections
nd smears were examined microscopically using a
eitz Laborlux microscope with a Leica camera at-
achment (Leica Microsystems, Wetzlar, Germany).
R Technique
The pelvic MRI technique employed T1-
eighted spin-echo (TE) and short inversion time
nversion recovery (STIR) techniques in the coronal
nd axial (transverse) planes and was designed to assess
he medullary cavities of both iliac bones, the lower
umbar vertebrae, both femoral heads, and the proxi-
al femoral shafts. Imaging was done using a Siemens
armony 1.0-T Magnetic Resonance System (Sie-
ens Medical Solutions, Malvern, Penn).
Table 3 schematically summarizes the appearances
xpected on the TE and STIR images for 6 different
able 2. Grading of Osteosclerosis
Grade Description
0 Average trabecular width 0.1-0.15 mm (normal range)
1 Average trabecular width 0.2 mm
2 Average trabecular width 0.3 mm
3 Average trabecular width 0.4 mm
4 Grade 3 plus new bone formation as indicated by new
osteoid formation >0.1 mm; or grade 3 plus knobby
bone areas (trabeculae with enlarged and rounded
ends)
5 Grade 4 plus knobby bone areasm
6 Osteosclerosis occupying >75% of marrow spacearrow elements, namely ﬁbrosis, tumor, ﬂuid, fat,
ormal hematopoietic cells, and osteosclerosis. Inter-
retation of marrow requires the understanding that
he TE signal is light (high) in fatty areas and dark
low) in areas of ﬂuid, ﬁbrosis, sclerosis, and tumor.
n STIR images, however, ﬁbrosis and fat are dark,
hereas water-containing components such as ﬂuid or
umor are of high signal intensity and, therefore, are
ortrayed as bright. Normocellular marrow is approx-
mately half fat and half water and, hence, is of inter-
ediate brightness with both methods. Osteosclerosis
nd cortical bone are dark to very dark on TE and
TIR images. Recent needle biopsy tracks (edema,
emorrhage) show a bright linear focus of ﬂuid on the
TIR image and a correspondingly dark appearance
n TE images. Older biopsy tracks (after several
eeks) generally display a dark linear image on TE
mages with variable intensity on STIR images (see
igures 4A and 4B).
These patterns on MRI allow a broad assessment of
very large marrow volume and locations of biopsy
ampling sites. Therefore, the combination of biopsy
nd MRI should provide a reliable estimate of the extent
nd severity of myeloﬁbrosis and an indication of how
epresentative a concurrent biopsy sample might be.
ransplantation
Donor and transplant characteristics are summa-
ized in Table 1.
Patients were conditioned for HCT as described
reviously [6]: 26 received targeted busulfan (BU)
lus cyclophosphamide (with the addition of thy-
oglobulin in 10) [13], 2 received ﬂudarabine plus
argeted BU [14] (1 with the addition of thymo-
lobulin), and 1 each received BU plus total body
rradiation (800 cGy) [15] or ﬂudarabine plus total
ody irradiation (200 cGy) [16]. The 2 autologous
ransplant recipients received only BU [17]. Graft-
ersus-host disease prophylaxis for the 29 allogeneic
ransplant recipients consisted of cyclosporine plus
able 3. Patterns of Magnetic Resonance Images
TE STIR
ibrosis Dark Dark
umor Dark Light
luid Dark Light
at Light Dark
ematopoiesis Intermediate Intermediate
ecent needle
track
Dark Light (needle track and local
edema)
ld needle
track
Dark Dark (except when space fills
with fluid as in Figure 4B)
steosclerosis Dark Dark
E, T1 spin echo; STIR, short inversion time inversion recovery.ethotrexate in 27, and 1 each received methotrex-
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G. E. Sale et al.1288te plus sirolimus or cyclosporine plus mycopheno-
ate mofetil, respectively [6].
Twelve patients received transplants from HLA-
dentical siblings, 17 from unrelated donors who were
LA-identical with the patients by high-resolution
yping, 1 from a syngeneic twin, and 2 received autol-
gous peripheral blood progenitor cells that had been
arvested after granulocyte colony-stimulating factor
timulation and cryopreserved until HCT [17]. Three
atients underwent the initial evaluation but, for var-
ous reasons, did not proceed to HCT.
At 3 months, before being discharged from the
ransplantation center, patients underwent a complete
igure 1. Patient with complete resolution of myeloﬁbrosis 1 year a
iffuse reticulin positivity (300). B, Reticulin stain at 1 year a
rogressive diminution of the dark (low signal) medullary pattern (T
ypical of more normal marrow at 3 months (TE 2H), and return to
TE 1.5H). This coronal section shows femoral and acetabular region
f 20 acquired through the pelvic marrow. D, TE transverse images
n the posterior iliac crests. E, STIR images show progression fr
ormocellular) with resolution of ﬁbrosis; same time sequence as in C anddeparture workup,” including marrow biopsy and
RI. Patients who at that time were receiving treat-
ent for graft-versus-host disease with glucocorti-
oids were started on prophylactic bisphosphonates
usually Fosamax 35 mg once a week). Subsequently,
atients were cared for by their hometown physicians
nd returned to the transplantation center for a re-
valuation approximately 1 year after transplantation.
onsent
All patients gave informed consent for enrollment
nto this study according to the procedures required
splantation. A, Bone marrow reticulin stain before transplantation.
nsplantation (grade 0-1). C, T1 spin-echo (TE) sequence shows
mogeneous [H]) and transition to a pale gray (intermediate) pattern
rmal, with scattered foci of low signal at 1 year after transplantation
e ilia and portions of the lower lumbar vertebrae on a selected image
he same timing as in C; similar changes from dark to light are seen
derately light (STIR 3, mildly hypercellular) to dark (STIR 0.5,fter tran
fter tra
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MRI for Myelofibrosis 1289y the institutional review board of the Fred Hutchin-
on Cancer Research Center (Seattle, Wash).
ESULTS
We ﬁrst carried out a cross-sectional review of
iopsies before HCT and MRI ﬁndings in all 35
atients to describe the spectrum and patterns of mar-
ow ﬁbrosis (and osteosclerosis) that were observed.
e next reviewed sequential studies in the same pa-
ients to deﬁne longitudinal (chronologic) changes in
iopsy and MRI, and we correlated those ﬁndings
ith the patients’ clinical course. Histologic and MRI
nalysis occurred independently (GES and BAP, re-
pectively); MRI reading was blinded as to biopsy
ndings and patient condition.
igure 2. Patient with refractory disease. A, Bone marrow reticulin
year after transplantation; no improvement (ﬁbers are still de
ransplantation (TE 4 homogeneous [H]) with little or no change
mprovement in the femoral head appearance at 1 year. D, TE MR
ppearance over 1 year. E, STIR sequence shows only modest chang
as interpreted as primarily due to decreased ﬂuid content without
mage, with extraosseous and intraosseous edema seen as a bright
epresentative of the marrow as a whole.retransplantation Assessment of Myelofibrosis
The initial biopsies, available in all 35 patients,
howed ﬁbrosis grades ranging from 2 to 4 as de-
cribed previously [11,12]. Osteosclerosis ranged from
bsent (grade 0) to severe (grade 6). MRI ﬁndings
efore HCT demontrated several patterns as illus-
rated in Figures 1-4, ranging from diffuse ﬁbrosis to
atchy patterns. There was no correlation of MRI
ndings and Lille score [18].
ongitudinal Assessment of Changes
n Myelofibrosis
Data on 21 patients in whom sequential studies
ere obtained are summarized in Tables 4 and 5. MRI
llowed a distinction of uniform from heterogeneous
efore transplantation, grade 3-4 ﬁbrosis (300). B, Reticulin stain
0). C, TE coronal MRI sequence documents ﬁbrosis before
nths (TE 4H) and 1 year (TE 4 patchy [P]). There is only slight
sterior iliac crests shows lack of change in improvement of skeletal
before transplantation (STIR 3H) to 1 year (STIR 1P). This change
hange in ﬁbrosis. Note fresh needle site on the right side of the left
near signal (arrowhead) and a linear vertical line. This image wasstain b
nse 30
at 3 mo
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G. E. Sale et al.1290atterns of myeloﬁbrosis in 3-4 lumbar vertebrae,
oth femoral heads, shafts, and iliac crests. Recent and
ld biopsy sites were identiﬁed, and agreement (or
isagreement) between the biopsy sites and the gen-
ral marrow appearance was determined.
Among the 11 patients with follow-up studies for
months (Table 4), 1 showed complete clearing of
yeloﬁbrosis by biopsy and MRI over this interval.
he remaining patients showed minimal evidence of
hanges in the marrow, although splenomegaly was
sually markedly decreased.
Among 10 patients followed for1 year (Table 5),
omplete clearing of ﬁbrosis was observed in 6. In 3
atients, the degree of ﬁbrosis decreased from grades
-4 to grades 1-2, and in 1 patient from grade 4 to
rade 3. However, in this patient, ﬁbrosis subse-
igure 3. Heterogeneous ﬁbrosis, TE coronal view. Heterogeneous
attern with a focal high signal region in the medial right femur
arrow) indicats an area of uninvolved hypocellular normal fatty
arrow.
igure 4. Needle tracks. Old and new needle biopsy sites are visib
E 4 homogeneous (H) to TE 2H at 1 year. Biopsy sites appear as
TIR image regresses from 2H to 1H at 1 year. The right panel (1
ew on the STIR image. B, STIR image at 1 year follow-up (com
arrow), with a crescent of bright periosteal edema and a linear white
n the left side (yellow arrowhead).uently progressed again, associated with disease re-
urrence as also documented by reappearance of pa-
ient cells (see below).
When there was discordance between biopsy re-
ults and overall MRI ﬁndings, the needle site was
sually shown to be in marrow different in appearance
rom that visualized elsewhere, ie, located in an area of
arrow not considered representative. A representa-
ive biopsy was deﬁned as a site that matched the
verall appearance of the anatomic areas visualized on
RI (posterior iliac crests, the acetabular region of
he ileum, the femoral heads and upper shafts, and the
umbar vertebrae). MRI ﬁndings were graded from 1
o 4 (for ﬁbrosis intensity) and designated as homo-
eneous or patchy on TE and STIR images in each
ase at each time point studied (before HCT, 3
onths, and 1 year).
In patients with homogeneous patterns, the biopsy
ite was deemed representative by deﬁnition. Discrep-
ncies were possible, however, in cases with patchy
istributions of ﬁbrosis. Here, the identiﬁcation of the
eedle track was useful in assessing possible sampling
error.”
The resolution of ﬁbrosis appeared fastest in the
emora, intermediate in iliac crests, and slowest in the
ertebrae.
Detailed image sequences of representative pa-
ients, 1 whose disease resolved and 1 whose disease
as refractory, are illustrated in Figures 1 and 2. The
RI studies of patient 13 showed regression from a
E image with diffuse dark marrow (TE 3 homoge-
eous) to a light (high signal) homogeneous pattern
TE 0) characteristic of clearing ﬁbrosis over a period
f 15 months (Figures 1A and 1B). The STIR images
howed a hypercellular-appearing (STIR bright) pat-
ern correlating with marrow histology by biopsy,
hich showed high cellularity along with interstitial
brosis before transplantation. Over 1 year, the STIR
E and STIR sequences (patient 20). A, TE series regressing from
l dark lines (black arrowheads) that remain visible in all 3 images.
ollow-up) shows a new needle track, which is better recognized as
th A, lower right). A new needle site is identiﬁed on the far right
owing the needle track ﬁlled with ﬂuid. An old needle site is presentle on T
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MRI for Myelofibrosis 1291attern reverted to a normal cellularity appearance.
he myeloﬁbrosis grade (3-4) and osteosclerosis grade
4) decreased to 0 over that interval. Patient 19 (Figure
) showed refractory disease. The scores before HCT
ere 4 for ﬁbrosis and 4 for osteosclerosis, with a
uggestion of histologic improvement at 3 months,
ut at 14 months diffuse ﬁbrosis was present with little
r no change by MRI on the TE or the STIR images.
linically the patient showed disease progression.
Several patients showed a heterogeneous MRI
attern before HCT, and the extremes of regression
ersus refractory disease were more difﬁcult to assess.
atient 12, for example, showed a large cellular patch
f fatty hematopoiesis in the femoral neck region
Figure 3), which persisted throughout the year’s fol-
ow-up. Other marrow regions remained patchy by
RI, although there was a heterogeneous pattern of
mprovement.
In patients with patchy MRI patterns, correlation
ith the biopsy site data appeared particularly impor-
ant. For example, Figures 4A and 4B show new and
ld needle sites, with the new sites displaying edema
uid as white lines in the posterior iliac crest and a
hite ﬂuid crescent (edema) adjacent to the perios-
eum. This ﬁnding was easily interpreted as an in-
ication that the biopsy site was not representative
f the overall marrow status when it was compared
ith the marrow in the iliac crests and other bones
able 4. Course and Outcome in 11 Patients with Myeloﬁbrosis followe
Patient
Identification
Before Transplantation At 3 Mon
MRI*
Histology†
MRI
TE STIR TE STIR
1 4H 4H 2 2H 1H
2 3H 3H 3 3P 1P
3 4H 4H 3 1H 0
4 3H 3H 3 3H 3H
5 3H 2H 1-2 2P 1H
6 3H 4H 2 2P 2P
7 3H 4H 2 2P 1P
8 4H 3H 3 2P 2P
9 4H 4H 3-4 3P 3P
10 3H 3H 2-3 3P 2P
11 1H 1H 1-2 2P 1H
, homogeneous; MRI, magnetic resonance image; OS, osteosclero
spin echo; NED, no evidence of disease; GVHD, graft-versus-h
Degree of estimated ﬁbrosis (1-4).
Grade according to Dekmezian et al [12].
Range, 80-120 days.
Three-month biopsy insufﬁcient for assessment; complete clearanithin the pelvic MRI study. sA subset of 10 patients (including 2 who had MRIs
nly until 3 months; Table 4) had serial biopsies
valuable for osteosclerosis up to 1 year. Six of the 10
atients showed complete resolution of osteosclerosis,
nd 4 showed regression by 2 grades. When total
istologic scores (myeloﬁbrosis plus osteosclerosis)
ere tallied for this subset of 10 patients, the median
mprovement in total scores was from 7.0 before
ransplantation to 0.5 after transplantation. Histologic
eatures of 1 of these patients are shown in Figures 5
nd 6.
Together the data suggest that 3 months and,
ore frequently, 1 year of follow-up was required to
onﬁdently diagnose histologic and MRI resolution of
arrow ﬁbrosis after HCT.
orrelation of Marrow Features
nd Clinical Course
Details of transplantation results have been pre-
ented elsewhere [6,17]. Clinical data in comparison
ith biopsy and MRI ﬁndings are summarized in Ta-
les 4 and 5. In the group of 11 patients who had the
ast MRI at 3 months (Table 4) but continued to be
ollowed, 7 showed partial clearing. There were 2
dditional patients who showed histologic clearing at
year (but did not have MRI data available at 1 year)
nd no evidence of disease. Two patients, 1 of whom
ad received an autologous transplant (patient 4),
Months after Hematopoietic Cell Transplantation
Commentslogy
Partial clearing on histology; marked clearing and
decreased spleen size on MRI. Patient died with
chronic GVHD.
2 of 4 sites cleared. Alive, NED.
Nearly complete clearing. Alive, NED.
-3 Partial clearing, then again progression. Died from
progressive disease.
Moderate improvement from a low baseline. Alive,
NED.
Histology unchanged over time; MRI showed resolution
in femur and acetabulum only. Alive, NED.
Moderate clearance on MRI by 3 mo; total clearance by
biopsy at 1 y. Alive, NED.
Partial clearing by MRI and histology. Alive, NED.
Partial clearing. Died with GVHD.
Partial (patchy) clearing; vertebrae lagging; spleen size
reduced by half. Alive, NED.
Patchy resolution. Alive, NED.
e; P, patchy; STIR, short tau inversion recovery; TE, T1-weighted
ease.
year.d for 3
ths‡
Histo
1-2
0
0-1
3-2
0
2
0§
2-3
3
1
0
sis grad
ost dishowed no regression of ﬁbrosis at 3 months by MRI
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G. E. Sale et al.1292r histologically and subsequently succumbed to their
isease. One patient showed signiﬁcant clearing of
arrow ﬁbrosis already by 3 months (patient 3) and
as shown to be a complete donor chimera.
All 10 patients who had longitudinal biopsy and
RI studies to 1 year achieved engraftment (Table 5).
ix patients in this group who showed complete res-
lution of ﬁbrosis at 1 year also were complete donor
ell chimeras (100% of CD3 and CD33 cells in the
arrow and blood were donor derived). One patient,
ho had received stem cells from an unrelated donor
patient 19), never showed any clearing of marrow
brosis and had disease progression. Three patients in
his group showed only partial clearing by 1 year but
ubsequently all achieved normal hematopoietic pa-
ameters with complete donor chimerism; no fol-
ow-up MRI studies were available.
ISCUSSION
In patients with hematologic malignancies, mar-
ow ﬁbrosis is a secondary phenomenon due to abnor-
al cytokine secretion by clonogenic hematopoietic
recursor cells. Fibrosis may lead to severe clinical
anifestations due to peripheral blood cytopenias,
able 5. Course and Outcome in 10 Patients with Myeloﬁbrosis followe
Patient ID
Before Transplantation At 3 Months
MRI Histology MRI H
TE STIR MF OS TE STIR
12 4H 2-3H 3-4 2 2-3P 2P
13 4H 3H 3-4 4 2H 2
14 4H 3H 3-4 4 2H 2H
15 3H 3H 3-4 4 2-3P 1-2P
16 2P 2H 2 NA 2P 2
17 4H 3H 3 NA 1-2P 1-2P
18 4H 2P 3-4 4 4P 2P
19 4H 1H 4 4 4H 2P
20 4H 2H 3 3 3H 1H
21 2P 3P 2 0 NA NA
F, myeloﬁbrosis grade; OS, osteosclerosis grade (OS grading was
inversion time inversion recovery (grades 1-4); H, homogenous
no evidence of disease.plenomegaly, and hypermetabolism. Manifestations tre progressive and generally refractory to conven-
ional therapy. We and others have shown that HCT
an cure the underlying hematopoietic malignancy
nd lead to regression of ﬁbrosis [5,6,10,17]. How-
ver, accurate assessment of the degree of marrow
brosis (and response to therapy) has been notoriously
ifﬁcult, requiring serial marrow biopsies that are sub-
ect to signiﬁcant sampling error. It has been sug-
ested that the use of MRI might be useful in disease
ssessment [19,20].
In the present study we showed that MRI can be
sed to assess the extent of marrow ﬁbrosis and to
onitor marrow responses to treatment with HCT or
isease recurrence and progression. In successfully
reated patients, regression of ﬁbrosis and osteoscle-
osis with bone remodeling was apparent as soon as 3
onths after HCT. The tempo of regression of ﬁbro-
is and osteosclerosis differed between patients, but a
orrelation with other parameters or predictive factors
as not possible within this limited cohort of patients.
esponse assessment was more difﬁcult in patients
ho presented with a patchy pattern of ﬁbrosis. It is
onceivable that the kinetics of resolution were related
o the clearance of residual clonal cells of the under-
ying malignancy, and prolonged mixed chimerism, ie,
least 1 Year after Hematopoietic Cell Transplantation
>1 Year
Comments
y MRI Histology
TE STIR MF OS
2P 1P 0-1 0 Histologic resolution. MRI
variable. Alive, NED.
0 0 0 0 Clearing of fibrosis by
histology and MRI.
Alive, NED.
1H 1H 0-1 0 Almost complete clearing.
Alive, NED.
0-1P 2-3P 0 1 Almost complete clearing.
Alive, NED.
1P 1P 0 NA Complete clearing. Alive,
NED.
1-2P 1P 0 NA Almost complete clearing.
Alive, NED.
3P 1P 2 1 Partial clearing on
histology and MRI.
Alive, NED.
4P 1H 4 2 Failed to clear. Slight
osteosclerosis
improvement. Died
from progressive
disease.
2H 1H 0 0 Almost complete clearing.
Alive, NED.
2P 1-2P 0-1 0 MRI patchy residual. Alive,
NED.
ilable on all samples); TE, T1 spin echo (grades 1-4); STIR, short
chy; MRI, magnetic resonance imaging; NA, not available; NED,d for at
istolog
MF
2-3
2
1
2
1-2
1
3
3
2-3
1-2
not ava
; P, pathe persistence of patient cells in addition to engrafted
d
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MRI for Myelofibrosis 1293onor cells after transplantation, as has been observed
n patients with myeloﬁbrosis [6]. In support of such a
oncept is the fact that, in patients in whom the
ematologic malignancy recurred, as determined by
he presence of clonal chromosomal markers or pro-
ressive increase in the proportion of patient cells,
RI studies showed regrowth or progression of mar-
ow ﬁbrosis. The number of patients with progressive/
ecurrent disease in the present cohort was too small
o determine whether MRI ﬁndings revealed evidence
f disease recurrence before it was evident clinically or
n the basis of changes in peripheral blood cell counts.
An unexpected observation was that the resolution
f myeloﬁbrosis over time proceeded at different rates
n different skeletal sites. The most rapid changes
ere seen in the femora and adjacent supra-acetabular
one. Although the explanation is not clear, it is plau-
ible that constant weight-bearing stress in these areas
ay hasten bone remodeling and turnover. The dif-
erent rates of remodeling further underscore the het-
igure 5. Osteosclerosis. A, Before transplantation, an extremely
ide trabecular bone with multiple osteoid lines and knobby pro-
ections characterizes this patient’s marrow biopsy (osteosclerosis
rade 5). B, One year after transplantation, the average trabecular
idth was within normal limits (osteosclerosis grade 1). Hematox-
lin and eosin stain, 250).rogeneity of ﬁbrosis in the skeleton, and caution ogainst basing a global assessment of the marrow sta-
us on a single marrow biopsy. The biopsy needle
ay, by chance, sample a site that is not indicative of
he current level of disease activity and may not detect
hanges associated with disease recurrence after
CT.
The present study suggests that MRI is useful for
he classiﬁcation of myeloﬁbrosis. However, a larger
ohort of patients will need to be studied to develop a
ore deﬁnitive MRI staging system for myeloﬁbrosis
and osteosclerosis) before the use of MRI can be
ecommended as a standard monitoring tool in pa-
ients with myeloﬁbrosis. Nevertheless, the present
tudy shows that MRI more than complements the
ndings from needle biopsies of marrow and adds
ccuracy and a more global perspective to the evalu-
tion of the status and evolution of myeloﬁbrosis. This
pproach coupled with in situ molecular studies on
iopsy specimens from MRI-deﬁned sites should en-
ble us to shed new light on processes involved in the
igure 6. Documentation of ﬁbrosis by vimentin staining. A, Vi-
entin immunohistology (immunoperoxidase stain) shows the lin-
ar staining of ﬁbroblasts and round cytoplasmic staining of other
esenchymal cells before transplantation. B, At 1 year after trans-
lantation, the vimentin staining shows nearly total disappearance
f the linear markings of ﬁbroblasts.
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